Figure 1: Schematic representation of Jericho-D study design
|
Number of Letters Difference |
n |
p |
Group 1 |
9.58±3.49 |
25 |
0.0075 |
Group 2 |
8.62±3.40 |
26 |
0.0130 |
Table 1: Visual acuity increase from baseline at 180 days follow-up
Group 1: intravitreal injection of etamsylate followed by sham-treatment. Group 2: sham-treatment followed by etamsylate intravitreal injection. Data are expressed as mean±SD of the difference from baseline in the number of letters read in the ETDRS optotype. Patients in etamsylate/sham group were intravitreally injected with 12.5 mg etamsylate and sham-operated at 90 days after injection. Patients in sham/etamsylate group were sham-operated at day 0 and injected with etamsylate 12.5 mg at day 90. p was determined by linear regression mixed model
with baseline BCVA included as covariate.
Figure 1: Schematic representation of Jericho-D study design
Figure 2: Intravitreal injection of etamsylate improves visual acuity in patients with dry age-related macular degeneration at 90 days follow-up
Tables at a glance
Figures at a glance